

Samsung BioLogics named best bio product firm in Asia

27 April 2017 | News

The biosimilar product manufacturing affiliate of Samsung Group said it won the recognition at the Asia-Pacific Bioprocessing Excellence Awards 2017 in Singapore for achieving improvements in quality and manufacturing speed. The biosimilar product manufacturing affiliate of Samsung Group said it won the recognition at the Asia-Pacific Bioprocessing Excellence Awards 2017 in Singapore for achieving improvements in quality and manufacturing speed.



The biosimilar product manufacturing affiliate of Samsung Group said it won the recognition at the Asia-Pacific Bioprocessing Excellence Awards 2017 in Singapore for achieving improvements in quality and manufacturing speed.

“By utilising the latest world-class facilities to both maximise production efficiency and striving for continual innovation to manufacture high quality biologics at a competitive price, Samsung aims to provide the best contract manufacturing service in the world,” a company official said.

The Asia-Pacific Bioprocessing Excellence Awards have been held on the sidelines of the Biologics Manufacturing Conference. They aim to recognise industry’s best practices and innovations that facilitate bio manufacturing businesses to enhance production speed, reduce costs and improve product quality, Samsung BioLogics said.

The biologics industry in the Asia-Pacific region is growing at breakneck speed. The region alone accounts for 30 per cent of the global biosimilar market. At the same time, this market has attracted biopharmaceutical companies with highly skilled human resources and cost competitiveness.

It is estimated that about half of the world’s new bioprocessing and biomanufacturing facilities are being built in Asia by both local companies and multinational entities, according to Samsung BioLogics.

The biosimilar arm of Samsung Group said its third plant is under construction and is expected to be completed within this year. The new plant, which will add 180,000 liters of biosimilar product manufacturing capacity to the company, is scheduled to begin operation in the fourth quarter of 2018 after validation.

Upon the start of operations at its third plant in 2018, Samsung BioLogics said it expects to become the world's largest contract manufacturing company for biologics with a total production capacity of 362,000 liters.